The Leukemia and Lymphoma Society has estimated that in the US approximately 160 people die daily from leukemia. While a number of multiple myeloma (bone marrow cancer) treatments are available, new therapies are critical for patients who suffer from disease recurrence. Preclinical studies are the foundation of novel bone marrow disorder treatments. For a variety of leukemias, bone marrow, a flexible material located in the interior of many bones, is a primary target. Bone marrow in long bones (i.e. the femur) is carries out the process of hematopoiesis, or red blood cell (RBC) synthesis. Radiation is typically not a suitable treatment for bone marrow leukemia as it may disrupt RBC production and cause subsequent immunodeficiency disorders. The bone marrow stromal, or BMS, cell line was first established from mammalian tissue and has since been used in a myriad of molecular biology research employing transfection for the investigation of these cells. The stroma is considered all tissues not directly involved in RBC synthesis. The BMS model is considered an adequate transfection host used for studying skin, among other forms, cancer. As transfection efficiency is critical in many biomolecular studies, Altogen Biosystems formulated cell-specific reagents to improve research quality.
The Altogen Biosystems pre-optimized proprietary cationic lipid formulated BMS2 and BMS transfection kits are available at:
[ Ссылка ]
